4-chloro-2-(hydroxymethyl)thiophenol | 120121-37-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯硫酚类
• 英文名称: 4-chloro-2-(hydroxymethyl)thiophenol
• 英文别名: 5-chloro-2-mercaptophenylmethanol；(5-chloro-2-sulfanylphenyl)methanol
• CAS: 120121-37-1
• 化学式: C₇H₇ClOS
• 分子量: 174.651
• InChiKey: VJTBYIVDTPQLIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  21.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-2-(hydroxymethyl)thiophenol 在 manganese(IV) oxide 、 sodium methylate 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 31.0h， 生成 5-(5-Chloro-2-hexylsulfanyl-phenyl)-imidazolidine-2,4-dione
  参考文献：
  名称：

  Rotationally restricted mimics of rigid molecules: nonspirocyclic hydantoin aldose reductase inhibitors

  摘要：

  Sorbinil (1), a spirocyclic hydantoin, is a potent inhibitor of the enzyme aldose reductase. Simulation of the rigid spirocyclic ring orientation found in sorbinil was achieved with nonspirocyclic 5-[5'-chloro-2'-(alkylsulfonyl)-phenyl]hydantoins and 5-[5'-chloro-2'-[(N-alkylamino)sulfonyl]phenyl]hydantoins. The 2'-substituent (SO2R) was sufficiently large to hinder rotation of the hydantoin ring, forcing an orientation similar to that of a spirocyclic hydantoin. Calculated conformational preference, X-ray data, and inhibitory IC50 values for these nonspirocyclic 2'-substituted (SO2R) phenylhydantoins are in accord with what is expected for spirocyclic hydantoins and comparable to those of sorbinil.

  DOI：

  10.1021/jm00126a011
• 作为产物：
  描述：

  4-氯-2-巯基苯甲酸 在 sodium hydroxide 作用下， 以 四氢呋喃 、 盐酸 、 水 、 乙酸乙酯 为溶剂， 以94%的产率得到4-chloro-2-(hydroxymethyl)thiophenol
  参考文献：
  名称：

  Treating diabetic complications with 5-(substituted phenyl)hydantoins

  摘要：

  一系列5-（取代苯基）海因酰脲及其药学上可接受的盐是醛糖还原酶抑制剂，可用作治疗慢性糖尿病并发症的药物；其中间体；以及制备该化合物的过程。

  公开号：

  US04452806A1

文献信息

• [EN] SUBSTITUTED IMIDAZOPYRIDAZINES<br/>[FR] IMIDAZOPYRIDAZINES SUBSTITUÉES
  申请人：BAYER PHARMA AG

  公开号：WO2012032031A1

  公开（公告）日：2012-03-15

  The present invention relates to substituted imidazopyridazine compounds of general formula (l), which are Mps -1 (Monopolar Spindle 1) Kinase inhibitors (also known as Tyrosine Threonine Kinase, TTK) in which R3, R5, and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通式(l)的取代咪唑吡啶并联化合物，这些化合物是Mps-1（单极纺锤体1）激酶抑制剂（也称为酪氨酸苏氨酸激酶，TTK），其中R3、R5和A如权利要求中所定义，以及制备所述化合物的方法，包括含有所述化合物的药物组合物和配方，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分组合使用时，用于治疗或预防过度增殖和/或血管生成紊乱。
• Azolyl methyl phenyl derivatives having aromatase inhibitory activity
  申请人：Mochida Pharmaceutical Co., Ltd.

  公开号：US05587392A1

  公开（公告）日：1996-12-24

  Compounds exerting excellent aromatase inhibitory activity in vivo and in vitro with higher specificity and greater safety are provided together with the salts thereof. Using the same, there are also provided, prophylactic agents and/or therapeutical agents of estrogen-dependent diseases, contraceptive agents for females, and aromatase inhibitory agents for use in the form of reagents for human or animals. The compounds are of the formula (I), wherein R.sup.2 is represented by the formula (II) or (III). ##STR1##

  提供在体内和体外具有出色的芳香化酶抑制活性、具有更高特异性和更大安全性的化合物，以及它们的盐。利用这些化合物，还提供了预防雌激素依赖性疾病的预防剂和/或治疗剂、女性避孕剂，以及用作人类或动物试剂的芳香化酶抑制剂。这些化合物的化学式为(I)，其中R.sup.2由化学式(II)或(III)表示。
• [EN] ANTIDIABETIC BICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016022448A1

  公开（公告）日：2016-02-11

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新化合物及其药用可接受的盐是G蛋白偶联受体40（GPR40）的激动剂，可能对通过G蛋白偶联受体40介导的疾病的治疗、预防和抑制有用。本发明的化合物可能有助于治疗2型糖尿病，以及通常与该疾病相关的病症，包括肥胖和脂质紊乱，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高甘油三酯血症。
• SUBSTITUTED IMIDAZOPYRIDAZINES
  申请人：Klar Ulrich

  公开号：US20130338133A1

  公开（公告）日：2013-12-19

  The present invention relates to substituted imidazopyridazine compounds of general formula (I), which are Mps-1 (Monopolar Spindle 1) Kinase inhibitors (also known as Tyrosine Threonine Kinase, TTK) in which R 3 , R 5 , and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式（I）的取代咪唑吡啶基化合物，它们是Mps-1（单极纺锤体1）激酶抑制剂（也称为酪氨酸苏氨酸激酶，TTK），其中R3，R5和A如权利要求所定义，以制备这些化合物的方法，包括所述化合物的制药组合物和配伍物，以及使用所述化合物制造用于治疗或预防疾病的制药组合物，特别是用作单一剂量或与其他活性成分联合使用，用于治疗或预防过度增生和/或血管生成障碍。
• 5-(Substituted phenyl) hydantoins
  申请人：PFIZER INC.

  公开号：EP0112620A1

  公开（公告）日：1984-07-04

  A series of 5-(substituted phenyl)hydantoins and pharmaceutically acceptable salts thereof are aldose reductase inhibitors useful as agents for treatment of chronic diabetic complications, processes for preparing said compounds, and pharmaceutical compositions containing them.

  一系列 5-(取代苯基)海因及其药学上可接受的盐类是醛糖还原酶抑制剂，可作为治疗慢性糖尿病并发症的药物、制备上述化合物的工艺以及含有这些化合物的药物组合物。